Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Lupus Erythematosus, Systemic | 18 | 2021 | 1380 | 3.37 | Why? |
| Sjogren's Syndrome | 5 | 2019 | 284 | 1.31 | Why? |
| Undifferentiated Connective Tissue Diseases | 2 | 2020 | 60 | 1.02 | Why? |
| Connective Tissue Diseases | 2 | 2021 | 187 | 0.87 | Why? |
| Pregnancy Complications | 3 | 2020 | 1388 | 0.75 | Why? |
| Polyarteritis Nodosa | 1 | 2017 | 25 | 0.72 | Why? |
| Joints | 1 | 2018 | 97 | 0.69 | Why? |
| Joint Diseases | 1 | 2018 | 122 | 0.67 | Why? |
| Mood Disorders | 2 | 2018 | 431 | 0.66 | Why? |
| Behcet Syndrome | 1 | 2018 | 136 | 0.65 | Why? |
| Remission Induction | 2 | 2017 | 950 | 0.62 | Why? |
| Menopause | 1 | 2017 | 136 | 0.59 | Why? |
| Antiphospholipid Syndrome | 3 | 2018 | 533 | 0.57 | Why? |
| Community Pharmacy Services | 1 | 2021 | 426 | 0.56 | Why? |
| Family Planning Services | 1 | 2017 | 236 | 0.50 | Why? |
| Lower Extremity | 1 | 2017 | 593 | 0.47 | Why? |
| Steroids | 2 | 2019 | 904 | 0.47 | Why? |
| Calcifediol | 1 | 2013 | 191 | 0.46 | Why? |
| Rheumatology | 2 | 2020 | 1213 | 0.45 | Why? |
| Antibodies, Antinuclear | 5 | 2018 | 234 | 0.43 | Why? |
| Muscle, Skeletal | 1 | 2017 | 915 | 0.42 | Why? |
| Autoimmune Diseases | 3 | 2018 | 1996 | 0.42 | Why? |
| Bipolar Disorder | 1 | 2018 | 744 | 0.41 | Why? |
| Pregnancy Outcome | 2 | 2020 | 3803 | 0.39 | Why? |
| Rheumatologists | 3 | 2021 | 346 | 0.35 | Why? |
| Raynaud Disease | 2 | 2018 | 86 | 0.34 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.28 | Why? |
| Deglutition Disorders | 2 | 2019 | 481 | 0.25 | Why? |
| Immunosuppressive Agents | 3 | 2017 | 6331 | 0.24 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.23 | Why? |
| Antirheumatic Agents | 3 | 2021 | 3023 | 0.21 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.20 | Why? |
| Salivary Glands, Minor | 1 | 2019 | 16 | 0.20 | Why? |
| Vitamin D Deficiency | 1 | 2013 | 1782 | 0.20 | Why? |
| Ocular Hypertension | 1 | 2019 | 35 | 0.19 | Why? |
| Coombs Test | 1 | 2018 | 66 | 0.19 | Why? |
| beta 2-Glycoprotein I | 1 | 2018 | 92 | 0.19 | Why? |
| Mixed Connective Tissue Disease | 1 | 2018 | 31 | 0.19 | Why? |
| Thyroiditis, Autoimmune | 1 | 2018 | 86 | 0.18 | Why? |
| Mucins | 1 | 2019 | 147 | 0.18 | Why? |
| Salivary Cystatins | 1 | 2017 | 2 | 0.18 | Why? |
| Submandibular Gland Diseases | 1 | 2017 | 6 | 0.18 | Why? |
| Complement System Proteins | 2 | 2018 | 380 | 0.18 | Why? |
| Health Services Accessibility | 2 | 2021 | 10697 | 0.17 | Why? |
| Pulse Therapy, Drug | 1 | 2017 | 137 | 0.17 | Why? |
| Fever of Unknown Origin | 1 | 2018 | 93 | 0.17 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.17 | Why? |
| Antibodies, Protozoan | 1 | 2017 | 121 | 0.16 | Why? |
| Leukopenia | 1 | 2018 | 280 | 0.16 | Why? |
| Rare Diseases | 1 | 2020 | 373 | 0.16 | Why? |
| Autoantibodies | 2 | 2018 | 2094 | 0.16 | Why? |
| Ribonucleoproteins | 1 | 2017 | 151 | 0.16 | Why? |
| Uveitis | 1 | 2019 | 233 | 0.15 | Why? |
| Myositis | 1 | 2019 | 185 | 0.15 | Why? |
| Cataract | 1 | 2019 | 186 | 0.15 | Why? |
| Electromyography | 1 | 2017 | 278 | 0.15 | Why? |
| Arthralgia | 1 | 2017 | 173 | 0.15 | Why? |
| Anemia, Hemolytic, Autoimmune | 1 | 2018 | 199 | 0.15 | Why? |
| Lupus Vasculitis, Central Nervous System | 1 | 2014 | 7 | 0.15 | Why? |
| Glaucoma | 1 | 2019 | 225 | 0.14 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.14 | Why? |
| False Positive Reactions | 1 | 2020 | 1338 | 0.14 | Why? |
| Rheumatic Diseases | 3 | 2020 | 2675 | 0.14 | Why? |
| Diagnosis, Differential | 3 | 2018 | 7220 | 0.14 | Why? |
| Predictive Value of Tests | 4 | 2020 | 9537 | 0.14 | Why? |
| Immunoradiometric Assay | 1 | 2013 | 2 | 0.14 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.14 | Why? |
| Hepatitis, Autoimmune | 1 | 2018 | 254 | 0.14 | Why? |
| Spondylitis, Ankylosing | 1 | 2017 | 231 | 0.14 | Why? |
| Arthritis | 1 | 2018 | 288 | 0.14 | Why? |
| Affect | 1 | 2018 | 549 | 0.13 | Why? |
| Europe | 5 | 2021 | 12702 | 0.12 | Why? |
| DNA | 1 | 2018 | 778 | 0.12 | Why? |
| Pregnancy | 4 | 2020 | 23879 | 0.12 | Why? |
| Janus Kinase Inhibitors | 1 | 2018 | 682 | 0.12 | Why? |
| Fertility | 1 | 2017 | 367 | 0.12 | Why? |
| Neuropsychological Tests | 1 | 2018 | 954 | 0.12 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.12 | Why? |
| Azetidines | 1 | 2018 | 722 | 0.12 | Why? |
| Humans | 35 | 2021 | 930598 | 0.12 | Why? |
| Scleroderma, Systemic | 1 | 2018 | 583 | 0.12 | Why? |
| Biopsy | 2 | 2018 | 2811 | 0.11 | Why? |
| Counseling | 1 | 2017 | 747 | 0.11 | Why? |
| Arthritis, Psoriatic | 1 | 2017 | 625 | 0.11 | Why? |
| Reproducibility of Results | 4 | 2020 | 11304 | 0.10 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2018 | 1165 | 0.10 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.10 | Why? |
| Female | 17 | 2021 | 380317 | 0.10 | Why? |
| Sulfonamides | 1 | 2018 | 1294 | 0.10 | Why? |
| Cognition Disorders | 1 | 2014 | 574 | 0.09 | Why? |
| Civil Defense | 1 | 2021 | 1687 | 0.09 | Why? |
| Self Report | 1 | 2021 | 3802 | 0.09 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.09 | Why? |
| MicroRNAs | 2 | 2019 | 1787 | 0.09 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.09 | Why? |
| Exanthema | 1 | 2018 | 1097 | 0.09 | Why? |
| Arthritis, Rheumatoid | 2 | 2018 | 2043 | 0.09 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.09 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 1458 | 0.09 | Why? |
| Lung Diseases, Interstitial | 1 | 2018 | 1476 | 0.08 | Why? |
| Consensus | 2 | 2018 | 6345 | 0.08 | Why? |
| Methylprednisolone | 1 | 2017 | 2107 | 0.08 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.08 | Why? |
| Prognosis | 3 | 2018 | 32490 | 0.08 | Why? |
| Adult | 13 | 2020 | 244371 | 0.08 | Why? |
| Drug Administration Schedule | 1 | 2013 | 2324 | 0.08 | Why? |
| Cognitive Dysfunction | 1 | 2018 | 1389 | 0.08 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.08 | Why? |
| Biological Products | 2 | 2020 | 2331 | 0.08 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.07 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.07 | Why? |
| North America | 2 | 2020 | 1400 | 0.07 | Why? |
| Male | 12 | 2021 | 367725 | 0.07 | Why? |
| Headache | 1 | 2014 | 2257 | 0.07 | Why? |
| Recurrence | 1 | 2013 | 3675 | 0.06 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.06 | Why? |
| Phenotype | 1 | 2013 | 4037 | 0.06 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.06 | Why? |
| Signal Transduction | 1 | 2019 | 7207 | 0.06 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.06 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.05 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.05 | Why? |
| Risk Factors | 4 | 2019 | 71621 | 0.05 | Why? |
| Contraindications, Drug | 1 | 2020 | 281 | 0.05 | Why? |
| Complement C4 | 1 | 2018 | 86 | 0.05 | Why? |
| Patient Selection | 1 | 2013 | 4560 | 0.05 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.05 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.05 | Why? |
| Deglutition | 1 | 2019 | 104 | 0.05 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.04 | Why? |
| Philippines | 1 | 2020 | 568 | 0.04 | Why? |
| Submandibular Gland | 1 | 2017 | 29 | 0.04 | Why? |
| Radionuclide Imaging | 1 | 2019 | 184 | 0.04 | Why? |
| Lupus Nephritis | 1 | 2018 | 113 | 0.04 | Why? |
| Adolescent | 5 | 2019 | 86841 | 0.04 | Why? |
| Toxoplasma | 1 | 2017 | 61 | 0.04 | Why? |
| Liver Cirrhosis, Biliary | 1 | 2017 | 42 | 0.04 | Why? |
| Esophagus | 1 | 2019 | 139 | 0.04 | Why? |
| Italy | 2 | 2019 | 38444 | 0.04 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.04 | Why? |
| Algorithms | 1 | 2014 | 7346 | 0.04 | Why? |
| Models, Statistical | 1 | 2014 | 5312 | 0.04 | Why? |
| Retreatment | 1 | 2017 | 186 | 0.04 | Why? |
| Biomarkers, Pharmacological | 1 | 2017 | 150 | 0.04 | Why? |
| Creatine Kinase | 1 | 2018 | 386 | 0.04 | Why? |
| Complement C3 | 1 | 2018 | 271 | 0.04 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.04 | Why? |
| Aged | 6 | 2019 | 215776 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2020 | 51949 | 0.04 | Why? |
| Etanercept | 1 | 2017 | 162 | 0.04 | Why? |
| Prospective Studies | 3 | 2017 | 43301 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Population Groups | 1 | 2017 | 212 | 0.04 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Cholesterol, HDL | 1 | 2018 | 439 | 0.04 | Why? |
| Eye | 1 | 2019 | 374 | 0.04 | Why? |
| Cross-Cultural Comparison | 1 | 2017 | 338 | 0.03 | Why? |
| Glycosylation | 1 | 2019 | 1255 | 0.03 | Why? |
| Mouth | 1 | 2019 | 622 | 0.03 | Why? |
| Cholesterol | 1 | 2018 | 660 | 0.03 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Adalimumab | 1 | 2017 | 389 | 0.03 | Why? |
| Visual Acuity | 1 | 2019 | 790 | 0.03 | Why? |
| Purines | 1 | 2018 | 816 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Platelet Count | 1 | 2018 | 1381 | 0.03 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.03 | Why? |
| Pharynx | 1 | 2019 | 1544 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Withholding Treatment | 1 | 2017 | 798 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Up-Regulation | 1 | 2019 | 2249 | 0.03 | Why? |
| Reference Standards | 1 | 2014 | 1163 | 0.03 | Why? |
| Time Factors | 1 | 2013 | 31397 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.02 | Why? |
| Pyrazoles | 1 | 2018 | 1791 | 0.02 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Physician-Patient Relations | 1 | 2017 | 1266 | 0.02 | Why? |
| Lymphopenia | 1 | 2018 | 2669 | 0.02 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2018 | 2093 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.02 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.02 | Why? |
| Computer Simulation | 1 | 2019 | 4982 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Brazil | 1 | 2020 | 12582 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.02 | Why? |
| ROC Curve | 1 | 2014 | 6024 | 0.01 | Why? |
| Saliva | 1 | 2017 | 4679 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 11367 | 0.01 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Child | 2 | 2018 | 70012 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Inflammation | 1 | 2019 | 13255 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2019 | 88759 | 0.01 | Why? |